The Coca-Cola Co K vs Viatris Inc — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: The Coca-Cola Co K is far larger — about 18.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Viatris Inc for 57 Days on average.
| KO | VTRS | |
|---|---|---|
Market Cap | $377.63B | $20.03B |
Volume | 14,894,568 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $18.27 |
52-Week Low | $66.37 | $9.74 |
Typical Hold Time | 154 Days | 57 Days |
Enterprise Value | $404.81B | $32.15B |
Dividend Yield | 2.42% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.77, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 28.56% net margin, and 44.23% ROE. Recent institutional buying activity and positive analyst sentiment (60% buy ratings) support the stock's upward trajectory. KO maintains its dividend aristocrat status with 64 consecutive years of dividend increases, paying $0.53 per share in the upcoming H2-26 distribution.
KO presents a compelling investment case with stable revenue growth, exceptional profitability, and strong institutional support. The stock trades at a premium valuation (P/E 26.36) but justifies it with consistent execution. Key risks include regional demand divergence in Asia and elevated debt levels. With a consensus price target of $95.75 offering 9% upside potential, KO remains a quality defensive holding for dividend-focused investors seeking stable returns.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →